

Masaki Yoshida

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6729591/masaki-yoshida-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

12
papers

416
citations

6
h-index

12
g-index

12
ext. papers

493
ext. citations

3.2
avg, IF

3.35
L-index

#	Paper	IF	Citations
12	Cardiovascular safety of vibegron, a new β -adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study. <i>Neurourology and Urodynamics</i> , 2021 , 40, 1651-1660	2.3	1
11	Variability of post-void residual urine volume and bladder voiding efficiency in patients with underactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021 , 13, 51-55	1.9	4
10	Clinical diagnostic criteria for detrusor underactivity: A report from the Japanese Continence Society working group on underactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021 , 13, 13-16	1.9	2
9	Tadalafil Improves Nocturia and Nocturia-Related Quality of Life in Patients with Benign Prostatic Hyperplasia (KYU-PRO Study). <i>Urologia Internationalis</i> , 2020 , 104, 587-593	1.9	4
8	Clinical characteristics and useful signs to differentiate detrusor underactivity from bladder outlet obstruction in men with non-neurogenic lower urinary tract symptoms. <i>International Journal of Urology</i> , 2020 , 27, 47-52	2.3	5
7	Efficacy of novel β adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. <i>International Journal of Urology</i> , 2019 , 26, 369-375	2.3	13
6	Vibegron, a Novel Potent and Selective β Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study. <i>European Urology</i> , 2018 , 73, 783-790	10.2	68
5	Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2017 , 9, 176-186	1.9	6
4	Frontal Lobe Function Correlates with One-Year Incidence of Urinary Incontinence in Elderly with Alzheimer Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 567-574	4.3	6
3	Frontal white matter hyperintensity predicts lower urinary tract dysfunction in older adults with amnesic mild cognitive impairment and Alzheimer's disease. <i>Geriatrics and Gerontology International</i> , 2016 , 16, 167-74	2.9	23
2	Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. <i>International Journal of Urology</i> , 2013 , 20, 193-201	2.3	66
1	Silodosin, a new α 1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. <i>BJU International</i> , 2006 , 98, 1019-24	5.6	218